乳腺癌术后放疗诱发性肉瘤的治疗进展  

Management for radiation-induced sarcoma

作　　者：胡婷婷[1] 苏逢锡[1] 

机构地区：[1]中山大学孙逸仙纪念医院乳腺肿瘤医学部,广州510120

出　　处：《岭南现代临床外科》2014年第3期339-341,344,共4页Lingnan Modern Clinics in Surgery

基　　金：国家自然科学基金(编号:81172524);国家自然科学基金(编号:81372817)

摘　　要：放疗诱发性肉瘤(radiation induced sarcoma,RIS)是一种罕见的、恶性程度较高的肿瘤,可发生于乳腺癌、妇科肿瘤、霍奇金淋巴瘤和其他类型肿瘤放射治疗后,而其中乳腺癌放疗诱发性肉瘤占较大的比例。目前,对于此类肿瘤的治疗仍是临床上一大难题,不管是手术治疗还是手术联合辅助放化疗,其5年生存率仍较低,且治疗后局部复发率很高。为提高临床医生对放疗诱发性肉瘤治疗方案的优化选择,改善患者预后,本文对目前针对放疗诱发性肉瘤的治疗进展做一综述。Radiation induced sarcoma （RIS） is a rare and highly malignant tumor, which mostly occurs in following radiation of breast cancer, gynecological cancer, Hodgkin＇s lymphoma and other types of tumor. Breast cancer radiation induced sarcoma accounted for the larger proportion. At present, the treatment for RIS is still a big challenge in the clinical settings. Whether it was operation therapy or adjuvant chemotherapy, the 5 years survival rate was low and local recurrencerate was high. To improve the prognosis of the patients and offer the clinicians more effective therapeutic regimen, we reviewed the current progresses in the treatment of radiation induced sarcoma.

关 键 词：放疗后诱发性肉瘤 乳腺癌 局部根治性切除术 化疗 放疗 

分 类 号：R655.8[医药卫生—外科学]